Rotavirus vaccines: Successes and challenges

Journal of Infection

Volumn 68, Issue SUPPL1, 2014, Pages

  Glass, Roger I ^a   Parashar, Umesh ^b   Patel, Manish ^b   Gentsch, Jon ^b   Jiang, Baoming ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Childhood diarrhea; Rotavirus; Vaccines

Indexed keywords

PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE;

ARTICLE; CLINICAL FEATURE; DIARRHEA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INTUSSUSCEPTION; MORTALITY; PREVALENCE; ROTAVIRUS INFECTION; VACCINE PRODUCTION; VIROLOGY; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

CHILDHOOD DIARRHEA; ROTAVIRUS; VACCINES;

DIARRHEA; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE FINANCING; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84889883941     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.09.010     Document Type: Article

References (59)

1. Glass R.I. Where are we now and where are we going?. Presented at the 8th International Rotavirus Symposium June 4, 2008, [Istanbul, Turkey].
2. Bishop R.F., Davidson G.P., Holmes I.H., Ruck B.J. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973, 2(7841):1281-1283.
3. Yolken R.H., Wyatt R.G., Barbour B.A., Kim H.W., Kapikian A.Z., Chanock R.M. Measurement of rotavirus antibody by an enzyme-linked immunosorbent assay blocking assay. J Clin Microbiol 1978, 8(3):283-287.
4. Kapikian A.Z., Hoshino Y., Chanock R.M., Perez-Schael I. Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Arch Virol Suppl 1996, 12:163-175.
5. Patel M.M., Glass R., Desai R., Tate J.E., Parashar U.D. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure?. Lancet Infect Dis 2012, 12(7):561-570.
6. Patel M.M., Steele D., Gentsch J.R., Wecker J., Glass R.I., Parashar U.D. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011, 30(Suppl. 1):S1-S5.
7. Rodriguez W.J., Kim H.W., Brandt C.D., Schwartz R.H., Gardner M.K., Jeffries B., et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 1987, 6(2):170-176.
8. Velazquez F., Calva J.J., Lourdes Guerrero M., Mass D., Glass R.I., Pickering L.K., et al. Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children. Pediatr Infect Dis J 1993, 12(1):54-61.
9. Rodriguez W.J., Kim H.W., Arrobio J.O., Brandt C.D., Chanock R.M., Kapikian A.Z., et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J Pediatr 1977, 91(2):188-193.
10. Blutt S.E., Kirkwood C.D., Parreno V., Warfield K.L., Ciarlet M., Estes M.K., et al. Rotavirus antigenaemia and viraemia: a common event?. Lancet 2003, 362(9394):1445-1449.
11. Patel M., Rench M.A., Boom J.A., Tate J.E., Sahni L.C., Hull J.A., et al. Detection of rotavirus antigenemia in routinely obtained serum specimens to augment surveillance and vaccine effectiveness evaluations. Pediatr Infect Dis J 2010, 29(9):836-839.
12. Lynch M., Lee B., Azimi P., Gentsch J., Glaser C., Gilliam S., et al. Rotavirus and central nervous system symptoms: cause or contaminant? Case reports and review. Clin Infect Dis 2001, 33(7):932-938.
13. Oishi I., Kimura T., Murakami T., Haruki K., Yamazaki K., Seto Y., et al. Serial observations of chronic rotavirus infection in an immunodeficient child. Microbiol Immunol 1991, 35(11):953-961.
14. Saulsbury F.T., Winkelstein J.A., Yolken R.H. Chronic rotavirus infection in immunodeficiency. J Pediatr 1980, 97(1):61-65.
15. Brandt C.D., Kim H.W., Rodriguez W.J., Arrobio J.O., Jeffries B.C., Stallings E.P., et al. Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 1983, 18(1):71-78.
16. Cook S.M., Glass R.I., LeBaron C.W., Ho M.S. Global seasonality of rotavirus infections. Bull World Health Organ 1990, 68(2):171-177.
17. Bresee J.S., Glass R.I., Ivanoff B., Gentsch J.R. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999, 17(18):2207-2222.
18. Cunliffe N.A., Dove W., Bunn J.E., Ben Ramadam M., Nyangao J.W., Riveron R.L., et al. Expanding global distribution of rotavirus serotype G9: detection in Libya, Kenya, and Cuba. Emerg Infect Dis 2001, 7(5):890-892.
19. Cunliffe N.A., Kilgore P.E., Bresee J.S., Steele A.D., Luo N., Hart C.A., et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull World Health Organ 1998, 76(5):525-537.
20. Kang G., Kelkar S.D., Chitambar S.D., Ray P., Naik T. Epidemiological profile of rotaviral infection in India: challenges for the 21st century. J Infect Dis 2005, 192(Suppl. 1):S120-S126.
21. Jiang V., Jiang B., Tate J., Parashar U.D., Patel M.M. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin 2010, 6(7).
22. Pitzer V.E., Viboud C., Lopman B.A., Patel M.M., Parashar U.D., Grenfell B.T. Influence of birth rates and transmission rates on the global seasonality of rotavirus incidence. J R Soc Interface 2011, 8(64):1584-1593.
23. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335(14):1022-1028.
24. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011, 365(4):337-346.
25. Bresee J.S., Marcus R., Venezia R.A., Keene W.E., Morse D., Thanassi M., et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J Infect Dis 2012, 205(9):1374-1381.
26. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204(7):980-986.
27. Black R.E., Greenberg H.B., Kapikian A.Z., Brown K.H., Becker S. Acquisition of serum antibody to Norwalk virus and rotavirus and relation to diarrhea in a longitudinal study of young children in rural Bangladesh. J Infect Dis 1982, 145(4):483-489.
28. Kapikian A.Z., Greenberg H.B., Cline W.L., Kalica A.R., Wyatt R.G., James H.D., et al. Prevalence of antibody to the Norwalk agent by a newly developed immune adherence hemagglutination assay. J Med Virol 1978, 2(4):281-294.
29. Linhares A.C., Melo V.R., Mascarenhas J.D., Gabbay Y.B., de Freitas R.B. Pattern of acquisition of rotavirus antibody in children followed up from birth to the age of three years. Rev Soc Bras Med Trop 1989, 22(1):25-29.
30. Bresee J.S., Hummelman E., Nelson E.A., Glass R.I. Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines. J Infect Dis 2005, 192(Suppl. 1):S1-S5.
31. Rotavirus surveillance worldwide - 2009. Wkly Epidemiol Rec 2011, 86(18):174-176.
32. WHO Generic protocols for (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community-based survey on utilization of health care services for gastroenteritis in children 2002, 1-67. Document WHO/V & B/0215 Geneva.
33. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(2):304-306.
34. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(5):565-572.
35. Parashar U.D., Alexander J.P., Glass R.I. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-12):1-13.
36. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta- analysis. Lancet Infect Dis 2012, 12(2):136-141.
37. Estes M.K., Kapikian A. Rotaviruses. Fields virology 2007, 1917-1974. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
38. Gentsch J.R., Laird A.R., Bielfelt B., Griffin D.D., Banyai K., Ramachandran M., et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005, 192(Suppl. 1):S146-S159.
39. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(9619):1181-1189.
40. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
41. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
42. WHO Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009, 84(50):533-540.
43. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, etal. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo- controlled trial. Lancet Aug 21;376(9741):606-14.
44. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(4):289-298.
45. Nelson E.A., Glass R.I. Rotavirus: realising the potential of a promising vaccine. Lancet 2010, 376(9741):568-570.
46. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, etal. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet Aug 21;376(9741):615-3.
47. Patel M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. J Infect Dis 2009, 200(Suppl. 1):S39-S48.
48. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008, 57(25):697-700.
49. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325(5938):290-294.
50. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Weinberg G.A., Hall C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011, 53(3):245-253.
51. de Oliveira L.H., Danovaro-Holliday M.C., Sanwogou N.J., Ruiz-Matus C., Tambini G., Andrus J.K. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. Pediatr Infect Dis J 2011, 30(Suppl. 1):S61-S66.
52. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362(4):299-305.
53. Richardson V., Parashar U., Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365(8):772-773.
54. Buttery J.P., Danchin M.H., Lee K.J., Carlin J.B., McIntyre P.B., Elliott E.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29(16):3061-3066.
55. Patel M.M., Lopez-Collada V.R., Bulhoes M.M., De Oliveira L.H., Bautista Marquez A., Flannery B., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364(24):2283-2292.
56. Patel M.M., Clark A.D., Sanderson C.F., Tate J., Parashar U.D. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med 2012, 9(10):e1001330.
57. Patel M.M. Rotavirus vaccination programmes. BMJ 2012, 345:e5286.
58. Tate J.E., Patel M.M., Cortese M.M., Lopman B.A., Gentsch J.R., Fleming J., et al. Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. Expert Rev Vaccines 2012, 11(2):211-220.
59. Jiang B., Gentsch J.R., Glass R.I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008, 26(52):6754-6758.